MannKind & United Therapeutics sign collaboration deal for PAH drug
Date: 2018-09-06   Author: Ojaswita Kutepatil  Category: #news

MannKind & United Therapeutics sign collaboration deal for PAH drug

Two of the renowned U.S. based biotechnology companies, MannKind Corporation and United Therapeutics have recently inked a deal for the former’s PAH drug candidate. Reportedly, the new partnership is expected to enhance the development and commercialization of MannKind’s formulation of treprostinil (Tre-T) in a dry powder form.

According to sources, the Tre-T drug is being studied in clinical trials to treat pulmonary arterial hypertension (PAH).

Under the terms of the agreement, it has been reported that United Therapeutics will be considering the development, regulatory, and commercial activities, while MannKind will be focusing on the manufacturing of the initial commercial & clinical supplies from its Danbury-based plant. Gradually, the long-term commercial supplies are expected to be manufactured by United Therapeutics.

The new partnership will bring an immediate upfront payment of USD 45 million to MannKind from United Therapeutics and will also include further development milestone payments of over USD 50 million, cite sources familiar with the matter. Moreover, United Therapeutics is also permitted to expand the license to include active ingredients for the treatment of pulmonary hypertension. However, each product optioned will be subject to payment to MannKind of up to USD 40 million in double-digit royalties and additional milestone payments.

The two companies have also inked an additional research deal for the products beyond the current scope of the agreement, under which, sources affirm that MannKind will receive an upfront payment of USD 10 million.

If industry experts are to be believed, the new partnership deal is a big win for MannKind and will provide it with a partial solution to its cash crunch, as United is a sizable company that controls much of the PAH market. For the record, the California-based biopharmaceutical major was predicted to go out of business before 2020.

As per the recent premarket trading, MannKind’s stock scaled by 59 percent, and could be just the start of the long-term uptrend.



About Author


Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market res...

Read More

More from Ojaswita


Post Recommendents

Bank of Beijing & ING announce joint venture to set up digital bank
Author: Paroma Bhattacharya

Bank of Beijing will reportedly hold 49% of the stake and ING will hold remaining 51% in the new digital bank

Bank of Beijing has announced that it plans to estab...


Jitjatjo closes new $11M funding round led by Morningside Technology
Author: Pankaj Singh

Reports confirm that Morningside Technology Ventures, a Hong Kong investment firm, has led a $11 million Series A funding round for Jitjatjo, which is a mobile staffing marketplace for hospitality industry in New York....


Grab to charge fee for ride cancellation in Malaysia from March 25
Author: Pankaj Singh

Reports confirm that from March 25 this year, Grab Malaysia would begin charging its passengers a fee for canceling rides and also those who are late to their hired cab, after a specific permitted time.